HTA & Access to Innovative Oncology Drugs in Europe


25 Sep 2018 14:30


European Parliament
Room A5E-2


Health & Consumers

Event Location


Event Description

Innovative healthcare drugs and therapies offer the potential to improve the lives of millions of people living with cancer in Europe, yet significant differences in time-to-access remain for most of the new therapeutic interventions. How to ensure effective innovations are accessible and affordable to all patients is a challenge facing all stakeholders in the field of cancer.

In light of the European Commission’s legislative proposal for future EU cooperation on Health Technology Assessment, the European Cancer Patient Coalition (ECPC) together with Elisabetta Gardini MEP (EPP, Italy) will host a high-level policy discussion organised in partnership with the Cancer Drug Development Forum (CDDF). The meeting will bring together patients, health stakeholders, academia, policymakers and industry to highlight the importance of a more harmonised approach to Health Technology Assessment for ensuring timely access to innovative oncology diagnostics and treatments, and equally for establishing a more meaningful and systematic involvement of patient organisations in the process.

Today, very few HTA agencies in Europe involve patients in their assessments and where public engagement is sought, the approaches vary. The European Commission’s proposal seeks to dismantle barriers to involving patients in Health Technology Assessment, by creating established methods for providing patient evidence, but more robust patient engagement schemes are needed at both the EU and Member State levels.

Cancer patients are the most important partners in the fight against cancer and all cancer-related challenges affecting our society today. Considering that they are the ultimate beneficiaries of innovation in medical technologies, patients’ needs, and preferences must be captured, when assessing the value of new therapies.

This session is part of a 2-day Multi-Stakeholder Workshop on Biomarkers and Patients’ Access to Personalized Oncology Drugs in Europe organised by the Cancer Drug Development Forum in collaboration with ECPC. The workshop will take place at the Thon Hotel EU in Rue de la Loi 75, Brussels and will host experts coming from academia, industry, and patients representative. 


European Capital Markets Institute
Intern (Research)
CEMR - Council of European Municipalities and Regions
Project Officer
Institut Jules Bordet
Grant Manager
CEMR - Council of European Municipalities and Regions
Statutory Affairs Officer
PROSAFE - The Product Safety Forum of Europe
Events & Operations Officer
ENoP - European Network of Political Foundations
Administrative Assistant
European Association of Public Banks (EAPB)
Team Assistant/Office Manager
Cambre Associates SA
EU Public Policy Consultant
Cambre Associates SA
PR Consultant